Core Viewpoint - Sihuan Pharmaceutical (02096) has seen its stock price increase by over 3%, currently trading at HKD 12.61, with a transaction volume of HKD 22.0187 million, following the announcement of a licensing agreement with AbbVie Inc. for the investigational drug SIM0500 [1] Group 1: Licensing Agreement - The agreement with AbbVie includes an upfront payment and potential milestone payments totaling up to USD 1.055 billion, along with tiered royalties based on net sales [1] - Sihuan Pharmaceutical's core product SIM0500 has received a USD 40 million milestone payment from AbbVie, indicating strong progress in its development [1] Group 2: Clinical Development - SIM0500 has been granted Fast Track designation by the FDA, with Phase I clinical data expected to be released within the year, aiming for concept validation [1] - The drug has demonstrated significantly superior anti-tumor activity compared to dual-antibody TCEs in preclinical studies, leading the global progress among competitors targeting the same pathway [1] Group 3: Innovation and Collaboration - The company’s innovative research and development system and platform technology capabilities continue to be validated, having secured multiple overseas licensing agreements valued at USD 1 billion [1]
港股异动 | 先声药业(02096)涨超3% 近日核心产品SIM0500获艾伯维4000万美元里程碑付款